CN101961347A - Medicinal composition for treating cancer and use thereof - Google Patents

Medicinal composition for treating cancer and use thereof Download PDF

Info

Publication number
CN101961347A
CN101961347A CN 201010541584 CN201010541584A CN101961347A CN 101961347 A CN101961347 A CN 101961347A CN 201010541584 CN201010541584 CN 201010541584 CN 201010541584 A CN201010541584 A CN 201010541584A CN 101961347 A CN101961347 A CN 101961347A
Authority
CN
China
Prior art keywords
inorganic acid
acid salt
pharmaceutical composition
tetravalence
pentavalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 201010541584
Other languages
Chinese (zh)
Other versions
CN101961347B (en
Inventor
雷在荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panzhihua Xingchen Vanadium & Titanium Co Ltd
Original Assignee
Panzhihua Xingchen Vanadium & Titanium Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panzhihua Xingchen Vanadium & Titanium Co Ltd filed Critical Panzhihua Xingchen Vanadium & Titanium Co Ltd
Priority to CN2010105415845A priority Critical patent/CN101961347B/en
Publication of CN101961347A publication Critical patent/CN101961347A/en
Application granted granted Critical
Publication of CN101961347B publication Critical patent/CN101961347B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)

Abstract

The invention relates to a medicinal composition for treating cancer and use thereof and belongs to the field of chemical medicaments. To solve the technical problem, the invention provides a medicinal composition for treating cancer. The medicinal composition for treating cancer comprises the following active ingredient of tetravalent V inorganic acid salt. Compared with like medicaments in market, the medicament has the advantages of obviously reducing the cost and lightening economical burden of a patient. Clinical researches prove that: the medicament does not have obvious toxic or side effect or increase pain to the body of the patient. The medicament has higher recovery rate, is a new option for treating the cancer, and has wide market prospect.

Description

A kind of medical composition and its use for the treatment of cancer
Technical field
The present invention relates to a kind of medical composition and its use for the treatment of cancer, belong to the chemical medicine field.
Background technology
Cancer, cerebral thrombosis, diabetes, nervous headache and insomnia are comparatively complicated difficult and complicated illness, and the patient suffers untold misery, and has a strong impact on patient's quality of life.At present the above-mentioned disease of treatment mainly adopt operative treatment and or expectant treatment, but no matter operative treatment and or expectant treatment, except costing an arm and a leg, its cure rate is all on the low side, and some treatment means also can increase the weight of patient's misery.
Vanadium is one of trace element necessary in the human body, and vanadium is extremely low at the intravital content of people, and insufficient total amount is 1 milligram in the body, mainly is distributed in internal organs, positions such as liver, kidney, thyroid especially, and content is also higher in the osseous tissue.Vanadium only is 5% at the gastrointestinal absorbance, and its absorption site is mainly at upper digestive tract.About 95% vanadium combines and carries with transferrins with ionic condition in the blood, so vanadium and ferrum can interact in human body.Vanadium is a many-side in the intravital function of people, and the most approved vanadium lacks the research to goat and white mouse that performance comes from report in 1987, and the goat that vanadium lacks shows the abortion ratio increase and milk yield reduces.In the white mouse experiment, the vanadium shortage causes growth inhibited, and the reproduction function is weak, the ratio increase of thyroid weight and body weight and the variation of plasma thyroid hormones concentration.At present, still indeterminate for the research of human body vanadium deficiency disease.
Heyliger in 1985 etc. find that for the first time vanadate has blood sugar reducing function to the diabetes white mouse, thereafter a series of animal experiment studies of numerous scientists show, vanadium is all effective to insulin dependent diabetes mellitus (IDDM) (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM), and is particularly effective to serious insulin resistant type animal.Vanadium has the same effect of insulin in human body, promote lipogenesis, suppresses the effect of decomposing.Its effect is to suppress glycogen heteroplasia enzymatic activity, reduces glyconeogenesis, suppresses the activity of tyrosine phospholipase, and plays the effect of receptor in insulin conducted signal path, thereby reduces hyperglycemia.
Summary of the invention
Technical problem to be solved by this invention provides a kind of pharmaceutical composition for the treatment of cancer.
The pharmaceutical composition that the present invention treats cancer comprises the inorganic acid salt of following active component: tetravalence V.
Further, better for the drug effect that makes medicine of the present invention, active ingredient in pharmaceutical of the present invention also comprises the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, better for the drug effect that makes medicine of the present invention, active ingredient in pharmaceutical of the present invention also comprises proper inorganic acid, and wherein, described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical of the present invention contained mineral acid, it was a solution dosage, and dissolving fully with consumption assurance rest activity composition of mineral acid gets final product.
Further, better for the drug effect that makes medicine of the present invention, active ingredient in pharmaceutical of the present invention also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10 -6～10 -3Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
Active ingredient in pharmaceutical of the present invention can only be the inorganic acid salt of tetravalence V.
Further, active ingredient in pharmaceutical of the present invention can also be the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, active ingredient in pharmaceutical of the present invention can also be the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
Further, active ingredient in pharmaceutical of the present invention can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10 -6～10 -3Doubly, the inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
Wherein, the inorganic acid salt of above-mentioned V is preferably the V salt of sulfate, chlorate, phosphoric acid.The inorganic acid salt of above-mentioned tetravalence V is preferably: VCl 4, VOCl 2, VOSO 4, (VO) 3(PO 4) 2, VOHPO 4Or VO (H 2PO 4) 2The inorganic acid salt of above-mentioned pentavalent V is preferably VOCl 3Or (VO 2) 2(SO 4) 3, VOPO 4, (VO) 2(HPO 4) 3Or VO (H 2PO 4) 3
Medicine of the present invention can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Pharmaceutical composition of the present invention can be the pharmaceutical dosage form of routine, and wherein, the dosage form of pharmaceutical composition of the present invention is preferably external preparation.Wherein, external preparation is preferably transdermal formulation.Further, described transdermal formulation is preferably: patch, varnish, liniment, aerosol, unguentum or lotion.
The present invention also provides aforementioned pharmaceutical compositions in the purposes that is used for preparing the medicine for the treatment of cancer.
Wherein, the following cancer of pharmaceutical composition preferred therapeutic of the present invention: pulmonary carcinoma, leukemia, breast carcinoma, uterus carcinoma, cervical cancer, the esophageal carcinoma or hepatocarcinoma.
The cost that medicine of the present invention is compared commercially available similar medicine is obviously lower, has alleviated patient's financial burden.Show through clinical research, use medicine of the present invention not see that obvious toxic and side effects is arranged, also can not increase painful to patient body.The cure rate of medicine of the present invention is higher, for treatment for cancer provides a kind of new selection, has vast market prospect.
The specific embodiment
The pharmaceutical composition that the present invention treats cancer comprises the inorganic acid salt of following active component: tetravalence V.
Further, better for the drug effect that makes medicine of the present invention, active ingredient in pharmaceutical of the present invention also comprises the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, better for the drug effect that makes medicine of the present invention, active ingredient in pharmaceutical of the present invention also comprises proper inorganic acid, and wherein, described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.When active ingredient in pharmaceutical of the present invention contained mineral acid, it was a solution dosage, and dissolving fully with consumption assurance rest activity composition of mineral acid gets final product.
Further, better for the drug effect that makes medicine of the present invention, active ingredient in pharmaceutical of the present invention also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10 -6～10 -3Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
Active ingredient in pharmaceutical of the present invention can only be the inorganic acid salt of tetravalence V.
Further, active ingredient in pharmaceutical of the present invention can also be the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
Further, active ingredient in pharmaceutical of the present invention can also be the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
Further, active ingredient in pharmaceutical of the present invention can also be the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10 -6～10 -3Doubly, the inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
Wherein, the inorganic acid salt of above-mentioned V is preferably the V salt of sulfate, chlorate, phosphoric acid.The inorganic acid salt of above-mentioned tetravalence V is preferably: VCl 4, VOCl 2, VOSO 4, (VO) 3(PO 4) 2, VOHPO 4Or VO (H 2PO 4) 2The inorganic acid salt of above-mentioned pentavalent V is preferably VOCl 3Or (VO 2) 2(SO 4) 3, VOPO 4, (VO) 2(HPO 4) 3Or VO (H 2PO 4) 3
Medicine of the present invention can adopt conventional method that above-mentioned each activity is made according to mixed in molar ratio, according to concrete needs, also can add acceptable accessories.
Pharmaceutical composition of the present invention can be the pharmaceutical dosage form of routine, and wherein, the dosage form of pharmaceutical composition of the present invention is preferably external preparation.
Discover through the present inventor, when pharmaceutical composition of the present invention is transdermal formulation, its drug effect is preferable, and administration by percutaneous absorption can be avoided contingent first pass effect of hepar of oral administration and gastrointestinal deactivation, reduces the side effect of gastrointestinal administration, prove through clinical research, during pharmaceutical composition administration by percutaneous absorption of the present invention, non-evident effect produces, and the patient can be according to self individual variation, regulate dosage, also can discontinue medication at any time.Therefore, the dosage form of pharmaceutical composition of the present invention is preferably transdermal formulation.Further, described transdermal formulation is preferably: patch, varnish, liniment, aerosol, unguentum or lotion.
When the dosage form of medicine of the present invention is lotion, when using, the patient medicine of the present invention can be added suitable quantity of water, make the pH value of solution reach the acceptable faintly acid scope of human body, soak then and use, get final product about general soak time 10min, during immersion, the vanadium plasma enters in the body, under physiological condition, element generation redox reaction and potential change, activation of active cell mitogen and adjusting metabolism, and then cholesterol reducing, triglyceride and glucose level, play diuresis and promote uric acid sodium excretion and anticancer effect, reach therapeutic purposes.
The present invention also provides aforementioned pharmaceutical compositions in the purposes that is used for preparing the medicine for the treatment of cancer.Wherein, the following cancer of pharmaceutical composition preferred therapeutic of the present invention: pulmonary carcinoma, leukemia, breast carcinoma, uterus carcinoma, cervical cancer, the esophageal carcinoma or hepatocarcinoma.
Below in conjunction with embodiment the specific embodiment of the present invention is further described, does not therefore limit the present invention among the described scope of embodiments.
The preparation of embodiment 1 medicine of the present invention
Molar concentration compounding pharmaceutical according to table 1.
The set of dispense of table 1 medicine of the present invention is than (mol/L)
Figure BDA0000031970880000041
Pharmaceutical dosage form is a lotion, and adding water during use, to be mixed with pH value be to soak behind 5.5 the solution or clean and use, and soak time is about 10min.
Test example 1 adopts Drug therapy breast carcinoma of the present invention
The patient opens * *: women, 45 years old.
The existing huge lump of left suppurative mastitis in 2008,20.6 centimetres of major diameters, 15.2 centimetres of minor axis, lump is high 3.1 centimetres, and be diagnosed as: infiltration ductal carcinomas of breast to examination in hospital (left lump in breast hollow needle puncture biopsy) in May, 2008.
Adopt medicine of the present invention (medicine of embodiment 1, numbering 1), wiping every day mammary gland tumor 4 times, and be mixed with after bath essence cleans treatment February with medicine of the present invention, left swelling of the breast piece obviously reduces, and skin is red, swollen partly to disappear.Continue treatment after 3 months, left swelling of the breast piece is contracted to 10.6 centimetres of major diameters, 6.2 centimetres of minor axis, and lump is high 2.0 centimetres, and the state of an illness tends towards stability.
Test example 2 adopts the Drug therapy esophageal carcinoma of the present invention
Patient Yu Lu * *: man, 42 years old
In March, 2009, the acataposis symptom appearred in the patient, was diagnosed as the esophageal carcinoma (epimere cancer in the esophagus, medullary, 3.5 centimetres of focuses) through certain hospital.
First visit can only be eaten semi-fluid food, swallow to be the devil, the feeling of stuffiness in chest, tastelessness, breathe hard, expectoration, skeletonize, voice are humble continuous, days two or three times, deficient pulse is little unable, tongue fur is thin in vain.
Use medicine of the present invention (medicine of embodiment 1, numbering 2) to be mixed with bath essence and clean treatment after 2 months, spirit is got better, and acataposis subtracts greatly.After treating 1 month again, the state of an illness is stable day by day.Do the check of X line barium meal; Focus does not have development.
Test example 3 adopts Drug therapy hepatocarcinoma of the present invention
Patient's Huang * *: the male 46 years old, has the custom of being addicted to drink for a long time.
Because of hepatocarcinoma existing knife-edge part after certain hospital has made resection operation also has pain, gas is tightly dizzy.Adopt medicine of the present invention (medicine of embodiment 1, numbering 3) to be mixed with bath essence and clean treatment after 1 month, everyway has been seen good effect.Arrive examination in hospital again, all are normal.
Test example 4 adopts Drug therapy pulmonary carcinoma of the present invention
The patient opens * *, the male 40 years old, has the long-term smoking history.
Be diagnosed as pulmonary carcinoma late period in June, 2008, repeatedly chemotherapy does not have positive effect, and health is become thin gradually, can not have a meal.
Adopt medicine of the present invention (medicine of embodiment 1, numbering 9) to be mixed with bath essence, 4 scourings every day.After 4 months, weight increase, lump dwindle about 2 centimetres, and the abdominal cavity lymph disappears, and continue to use Drug therapy of the present invention after 2 months, and it is normal that health is recovered substantially.
Test example 5 adopts Drug therapy pulmonary carcinoma of the present invention
Patient Tang * *, women, 55 years old.
Cough appears at the beginning of the patient 2008, sputum mixed with blood, and accompany left breast dull pain symptom, be diagnosed as inferior lobe of right lung adenocarcinoma through hospital.
Adopt medicine of the present invention (medicine of embodiment 1, numbering 10) to be mixed with bath essence, 4 scourings every day.After 1 month, symptoms such as patient's spitting of blood, asthma, chest pain disappear substantially, through hospital's check, leave over right side thymus to thicken, and it is normal that health is recovered substantially.
Test example 6 adopts Drug therapy leukemia of the present invention
The patient is surplus * *, women, 60 years old.
In February, 2009 unexpected epistaxis, whole body tiredness is unable, pale complexion is diagnosed as acute leukemia M3 through examination in hospital.
Adopt medicine of the present invention (medicine of embodiment 1, numbering 6) to be mixed with bath essence, 5 scourings every day.After 1 15th day of a month, check bone marrow, report bone marrow is alleviated fully.Continue to strengthen treatment 5 months, check bone marrow, report bone marrow recovers normal level, does not occur the epistaxis situation during the after treatment again.

Claims (15)

1. treat the pharmaceutical composition of cancer, it is characterized in that comprising the inorganic acid salt of following active component: tetravalence V.
2. pharmaceutical composition according to claim 1 is characterized in that its active component also comprises the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
3. pharmaceutical composition according to claim 1 and 2 is characterized in that: described active component also comprises proper inorganic acid, and wherein, described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
4. according to each described pharmaceutical composition of claim 1～3, it is characterized in that: described active component also comprises the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge; Wherein, the inorganic acid salt content of K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10 -6～10 -3Doubly; The inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
5. pharmaceutical composition according to claim 1 is characterized in that its active component is the inorganic acid salt of tetravalence V.
6. pharmaceutical composition according to claim 1 is characterized in that its active component is the inorganic acid salt of tetravalence V and the inorganic acid salt of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%.
7. pharmaceutical composition according to claim 1 is characterized in that its active component is the inorganic acid salt of tetravalence V, inorganic acid salt and the proper inorganic acid of pentavalent V; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid.
8. pharmaceutical composition according to claim 1 is characterized in that its active component is the inorganic acid salt of K, Na, Fe, Al, Ti, Se, Li and/or Ge, the inorganic acid salt of tetravalence V, the inorganic acid salt of pentavalent V and proper inorganic acid; Wherein, the content of the inorganic acid salt of pentavalent V be tetravalence V the inorganic acid salt mole 0.5%～5%; Described mineral acid is hydrochloric acid, sulphuric acid or phosphoric acid; The inorganic acid salt content of described K, Na, Fe, Al, Ti, Se, Li, Ge be respectively V the inorganic acid salt integral molar quantity 10 -6～10 -3Doubly, the inorganic acid salt of described K, Na, Fe, Al, Ti, Se, Li, Ge is chlorate, sulfate or phosphate.
9. according to each described pharmaceutical composition of claim 1～8, it is characterized in that: the inorganic acid salt of described V is the V salt of sulfate, chlorate, phosphoric acid.
10. pharmaceutical composition according to claim 9 is characterized in that: the inorganic acid salt of described tetravalence V is: VCl 4, VOCl 2, VOSO 4, (VO) 3(PO 4) 2, VOHPO 4Or VO (H 2PO 4) 2The inorganic acid salt of described pentavalent V is VOCl 3Or (VO 2) 2(SO 4) 3, VOPO 4, (VO) 2(HPO 4) 3Or VO (H 2PO 4) 3
11. according to each described pharmaceutical composition of claim 1～10, it is characterized in that: the dosage form external preparation of described pharmaceutical composition.
12. pharmaceutical composition according to claim 11 is characterized in that: the dosage form transdermal formulation of described pharmaceutical composition.
13. pharmaceutical composition according to claim 12 is characterized in that: described transdermal formulation is patch, varnish, liniment, aerosol, unguentum or lotion.
14. each described pharmaceutical composition of claim 1～13 is in the purposes that is used for preparing the medicine for the treatment of cancer.
15. purposes according to claim 14 is characterized in that: described cancer is pulmonary carcinoma, leukemia, breast carcinoma, uterus carcinoma, cervical cancer, the esophageal carcinoma or hepatocarcinoma.
CN2010105415845A 2010-06-24 2010-11-12 Medicinal composition for treating cancer and use thereof Active CN101961347B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2010105415845A CN101961347B (en) 2010-06-24 2010-11-12 Medicinal composition for treating cancer and use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201010208132.5 2010-06-24
CN201010208132 2010-06-24
CN201010216341 2010-07-02
CN201010216341.4 2010-07-02
CN2010105415845A CN101961347B (en) 2010-06-24 2010-11-12 Medicinal composition for treating cancer and use thereof

Publications (2)

Publication Number Publication Date
CN101961347A true CN101961347A (en) 2011-02-02
CN101961347B CN101961347B (en) 2011-12-21

Family

ID=43450946

Family Applications (20)

Application Number Title Priority Date Filing Date
CN2010102988277A Active CN101953846B (en) 2010-06-24 2010-09-30 Application of medicinal composition to preparing medicament for treating diabetes
CN2010102980383A Active CN101947238B (en) 2010-06-24 2010-09-30 Pharmaceutical composition for treating cancer and application thereof
CN2010105414518A Active CN101978965B (en) 2010-06-24 2010-11-12 Use of medicine in treating diabetes
CN2010105415845A Active CN101961347B (en) 2010-06-24 2010-11-12 Medicinal composition for treating cancer and use thereof
CN2011101254105A Pending CN102309512A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating rheumatism
CN2011101254177A Pending CN102309513A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating hypertensive disease
CN2011101255659A Pending CN102309517A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating rheumatism
CN201110125808.9A Active CN102302511B (en) 2010-06-24 2011-05-16 Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction
CN201110125431.7A Active CN102302510B (en) 2010-06-24 2011-05-16 Medicinal composition and application thereof
CN2011101258093A Pending CN102309518A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating anemia
CN2011101252951A Pending CN102309509A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of analgesic drugs
CN2011101251677A Pending CN102309506A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating osteoporosis
CN2011101251785A Pending CN102309507A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of analgesic drugs
CN 201110125280 Pending CN102309508A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating anemia
CN2011101253672A Pending CN102309511A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating insomnia
CN2011101254196A Pending CN102309514A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating hypertensive disease
CN2011101254209A Pending CN102309515A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating insomnia
CN2011101253009A Pending CN102309510A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating osteoporosis
CN2011101250956A Pending CN102309505A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating organic sexual dysfunction
CN 201110125426 Pending CN102309516A (en) 2010-06-24 2011-05-16 Drug composition and application thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN2010102988277A Active CN101953846B (en) 2010-06-24 2010-09-30 Application of medicinal composition to preparing medicament for treating diabetes
CN2010102980383A Active CN101947238B (en) 2010-06-24 2010-09-30 Pharmaceutical composition for treating cancer and application thereof
CN2010105414518A Active CN101978965B (en) 2010-06-24 2010-11-12 Use of medicine in treating diabetes

Family Applications After (16)

Application Number Title Priority Date Filing Date
CN2011101254105A Pending CN102309512A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating rheumatism
CN2011101254177A Pending CN102309513A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating hypertensive disease
CN2011101255659A Pending CN102309517A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating rheumatism
CN201110125808.9A Active CN102302511B (en) 2010-06-24 2011-05-16 Application of medicinal composition to preparation of medicine for treating organic sexual dysfunction
CN201110125431.7A Active CN102302510B (en) 2010-06-24 2011-05-16 Medicinal composition and application thereof
CN2011101258093A Pending CN102309518A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating anemia
CN2011101252951A Pending CN102309509A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of analgesic drugs
CN2011101251677A Pending CN102309506A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating osteoporosis
CN2011101251785A Pending CN102309507A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of analgesic drugs
CN 201110125280 Pending CN102309508A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating anemia
CN2011101253672A Pending CN102309511A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating insomnia
CN2011101254196A Pending CN102309514A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating hypertensive disease
CN2011101254209A Pending CN102309515A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating insomnia
CN2011101253009A Pending CN102309510A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating osteoporosis
CN2011101250956A Pending CN102309505A (en) 2010-06-24 2011-05-16 Application of drug composition in preparation of drugs for treating organic sexual dysfunction
CN 201110125426 Pending CN102309516A (en) 2010-06-24 2011-05-16 Drug composition and application thereof

Country Status (1)

Country Link
CN (20) CN101953846B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398788A (en) * 2014-11-25 2015-03-11 孙莉莉 Traditional Chinese medicine electuary for treating insomnia and preparation method for traditional Chinese medicine electuary
CN106692546A (en) * 2015-11-14 2017-05-24 张立 Medicinal liquor for treating rheumatism and ostealgia
CN107375254A (en) * 2017-08-30 2017-11-24 李炜 A kind of external plaster and its application method for being used to treat diabetes
CN107485706A (en) * 2017-09-01 2017-12-19 仲崇允 A kind of Chinese medicine for treating breast cancer
CN114177196A (en) 2020-09-14 2022-03-15 湖南方升泰医药科技有限公司 Vanadium compounds for use in methods of treating pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437503A (en) * 2006-02-21 2009-05-20 阿斯特鲁姆医疗有限公司 Compositions to reduce blood glucose levels and treat diabetes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
IL121748A0 (en) * 1997-09-11 1998-02-22 Yeda Res & Dev Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them
CN1118243C (en) * 1999-12-17 2003-08-20 王将克 Nutritive soybean-pumpkin powder
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
CN1178946C (en) * 2000-11-28 2004-12-08 昆明贵金属研究所 Vanadium compound and its preparing process and usage
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
CN1179659C (en) * 2002-05-20 2004-12-15 郑军武 Prep. of vanadium-enriched nutrient extender
CN1413727A (en) * 2002-09-09 2003-04-30 凌一峰 Composite medicine for radical curing AIDS
CN1187091C (en) * 2002-09-24 2005-02-02 浙江大学 Oral vanadium replenishing agent with bimetallic oxide as carrier and its prepn and usage
CN1460472A (en) * 2003-06-06 2003-12-10 乐益 Biquanide vanadium complex plaster preparation for curing diabetes and its application
FI121915B (en) * 2004-02-06 2011-06-15 Neurofood Ab Oy Composition for the treatment of psoriasis
US20070066682A1 (en) * 2005-07-01 2007-03-22 Exposito Miriam R Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus
WO2007043606A1 (en) * 2005-10-12 2007-04-19 Genolac Bl Corporation Antidiabetic agent comprising anionic polyamino acid-metal complex
CN1846711A (en) * 2006-04-25 2006-10-18 苟仕金 Balanced solution with trace elements for extracorporeal culture of bezoar and its prepn process
CN101033239A (en) * 2007-01-31 2007-09-12 辽宁师范大学 Preparation and structure of novel para-insulin pharmaceutical model compound
CN101362684A (en) * 2008-07-23 2009-02-11 郑德龙 Solution containing vanadium oxalate and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437503A (en) * 2006-02-21 2009-05-20 阿斯特鲁姆医疗有限公司 Compositions to reduce blood glucose levels and treat diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《中国药物与临床》 20061130 张玲 《钒的医学应用研究进展》 843-845 第6卷, 第11期 2 *

Also Published As

Publication number Publication date
CN102309508A (en) 2012-01-11
CN102302511B (en) 2015-06-03
CN102309510A (en) 2012-01-11
CN101947238A (en) 2011-01-19
CN101947238B (en) 2011-12-21
CN102309515A (en) 2012-01-11
CN102309506A (en) 2012-01-11
CN102309517A (en) 2012-01-11
CN102309505A (en) 2012-01-11
CN101961347B (en) 2011-12-21
CN102309511A (en) 2012-01-11
CN102309516A (en) 2012-01-11
CN101978965A (en) 2011-02-23
CN102302511A (en) 2012-01-04
CN101953846A (en) 2011-01-26
CN102309512A (en) 2012-01-11
CN102309514A (en) 2012-01-11
CN102309509A (en) 2012-01-11
CN102309513A (en) 2012-01-11
CN102309507A (en) 2012-01-11
CN102302510B (en) 2014-04-23
CN102302510A (en) 2012-01-04
CN101978965B (en) 2011-12-28
CN102309518A (en) 2012-01-11
CN101953846B (en) 2011-12-28

Similar Documents

Publication Publication Date Title
CN101961347B (en) Medicinal composition for treating cancer and use thereof
US20060275505A1 (en) Method and composition for increasing the alkalinity of the body
CN102370730B (en) Self-heated traditional Chinese medicine (TCM) emplastrum for treating osteoarthritis
CN101953848B (en) Medicament for treating cancer and application thereof
CN102366501B (en) Self-heated traditional Chinese medicine (TCM) emplastrum for improving sleep quality
CN101972273B (en) Application of medicine in preparing medicines for treating diabetes mellitus
US20060292218A1 (en) Agent having a destructive effect on malignant tumors and method for the production thereof
KR100584214B1 (en) The method of manufacturing potentiator using oyster shell powder
PL225149B1 (en) Water-soluble, stable complexes of gold (III), a method for preparing hydrogen-soluble, stable complexes of gold (III) and their use
Curreri et al. Advances in the clinical care of burned patients
CN110302266A (en) A kind of hypoglycemic composition and preparation method thereof
CN102106978B (en) Medicament for treating nephritis
FB described in L858, and consists in rolling the_pa'; 1 i
Eddowes Jlbstracts from£ urrtnt mtdi (a.£ ittraturt.
CN107714779A (en) A kind of preparation method of the Chinese medicine composition of effectively treatment tinea pedis
PAIN et al. wearying, aching kind, more connected with debility, and requiring stimulating
CN106727558A (en) It is a kind of to treat medicine of stomach cancer and its preparation method and application
CN106581637A (en) Cancer treatment medicine, and preparation method and application thereof
Dougall Abstract of a Year's (1893) Medical Work in Wards 1, 2, and 9 of the Glasgow Royal Infirmary, with a Few Details of Some Rarer Cases, and Remarks on Treatment.
Dioxidum et al. TONICS (CONTINUED).
懿SURGICAL eiS ee SLS mmmmmmTlkkS
CN101837021A (en) American cockroach medicinal composition for curing gastritis and peptic ulcers and preparation method thereof
CN105078950A (en) Composite preparation containing zinc, magnesium and calcium ions and preparing method of composite preparation
CN101229253A (en) Compounds for control appetite primness and preparing method thereof
WO2011160444A1 (en) Pharmaceutical composition comprising vanadium and its use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant